248 related articles for article (PubMed ID: 35657688)
21. PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin.
Besse-Patin A; Jeromson S; Levesque-Damphousse P; Secco B; Laplante M; Estall JL
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4285-4290. PubMed ID: 30770439
[TBL] [Abstract][Full Text] [Related]
22. Impaired hepatic glucose metabolism and liver-α-cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4α (Hnf4a) gene.
Thymiakou E; Tzardi M; Kardassis D
Metabolism; 2023 Feb; 139():155371. PubMed ID: 36464036
[TBL] [Abstract][Full Text] [Related]
23. The biology of glucagon and the consequences of hyperglucagonemia.
Wewer Albrechtsen NJ; Kuhre RE; Pedersen J; Knop FK; Holst JJ
Biomark Med; 2016 Nov; 10(11):1141-1151. PubMed ID: 27611762
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
[TBL] [Abstract][Full Text] [Related]
26. The Regulation and Secretion of Glucagon in Response to Nutrient Composition: Unraveling Their Intricate Mechanisms.
Zhang J; Zheng Y; Martens L; Pfeiffer AFH
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764697
[TBL] [Abstract][Full Text] [Related]
27. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.
Junker AE; Gluud LL; van Hall G; Holst JJ; Knop FK; Vilsbøll T
J Hepatol; 2016 Apr; 64(4):908-15. PubMed ID: 26626496
[TBL] [Abstract][Full Text] [Related]
28. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
[TBL] [Abstract][Full Text] [Related]
29. The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes.
Gilon P
J Mol Biol; 2020 Mar; 432(5):1367-1394. PubMed ID: 31954131
[TBL] [Abstract][Full Text] [Related]
30. Hepatic glucagon action: beyond glucose mobilization.
Kajani S; Laker RC; Ratkova E; Will S; Rhodes CJ
Physiol Rev; 2024 Jul; 104(3):1021-1060. PubMed ID: 38300523
[TBL] [Abstract][Full Text] [Related]
31. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
32. Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling.
Galsgaard KD; Winther-Sørensen M; Pedersen J; Kjeldsen SAS; Rosenkilde MM; Wewer Albrechtsen NJ; Holst JJ
Am J Physiol Endocrinol Metab; 2019 Apr; 316(4):E660-E673. PubMed ID: 30807215
[TBL] [Abstract][Full Text] [Related]
33. Amino acids and the changing face of the α-cell.
Hamilton A; Eliasson L; Knudsen JG
Peptides; 2023 Aug; 166():171039. PubMed ID: 37295651
[TBL] [Abstract][Full Text] [Related]
34. Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion.
Bethea M; Bozadjieva-Kramer N; Sandoval DA
Endocrinology; 2021 Oct; 162(10):. PubMed ID: 34318874
[TBL] [Abstract][Full Text] [Related]
35. The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease.
Galsgaard KD
J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33333850
[TBL] [Abstract][Full Text] [Related]
36. Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia.
Suppli MP; Lund A; Bagger JI; Vilsbøll T; Knop FK
Med Hypotheses; 2016 Jan; 86():100-3. PubMed ID: 26547273
[TBL] [Abstract][Full Text] [Related]
37. Metabolic regulation of glucagon secretion.
Armour SL; Stanley JE; Cantley J; Dean ED; Knudsen JG
J Endocrinol; 2023 Sep; 259(1):. PubMed ID: 37523232
[TBL] [Abstract][Full Text] [Related]
38. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
39. Glucagon receptor signaling in metabolic diseases.
Wewer Albrechtsen NJ
Peptides; 2018 Feb; 100():42-47. PubMed ID: 29412830
[TBL] [Abstract][Full Text] [Related]
40. The liver-alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels.
Gar C; Haschka SJ; Kern-Matschilles S; Rauch B; Sacco V; Prehn C; Adamski J; Seissler J; Wewer Albrechtsen NJ; Holst JJ; Lechner A
Diabetologia; 2021 Mar; 64(3):512-520. PubMed ID: 33275161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
